We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
New RNS out on successful meeting with FDA regarding triple immunotherapy for head and neck cancer . See also
https://www.pdsbiotech.com/index.php/investors/news-center/press-releases/news-2023
FLORHAM PARK, N.J., Feb. 27, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for cancer and infectious disease, announced the successful completion of a Type B meeting with the U.S. Food and Drug Administration (FDA) for a combination therapy of PDS0101, PDS0301 and an FDA-approved immune checkpoint inhibitor (ICI) for the treatment of recurrent/metastatic human papilloma virus (HPV)-positive, ICI refractory head and neck cancer. Head and neck cancers are the most common of all HPV-positive cancers and the number of cases is growing rapidly, according to the National Cancer Institute (NCI), one of the National Institutes of Health (NIH). There remains a critical unmet medical need to develop new treatment options for patients who have failed treatment with ICIs. ….
The new ProAxis website has finally gone live.
Next will be their annual update.
I bought these a week ago in the 70's. Here we are in the 80's already....and it still looks a very good price.
Current share price is 40% of current NAV this has an awful long way to go. There is massive upside to their investments on top of current price IMHO
£16k ain’t a little punt
I’m still lonely in this room drinking special brew hick
People missing this one
Paper version of the IC mag hit the streets over the weekend, so expecting more buying today.
GLA
80 to buy
Definitely something going on I’m sure
After last week I think it might get a little busy again
That is a lot going on and if one or two get a break this should be a lot more than this
For those new to NSCI, have a look at the portfolio listed on the website. It will give you a good feel for the potential of this company.
https://netscientific.net/portfolio/emv-capital/
If this was currently sat at £1.20-£1.50 it wouldn't be over priced
oooh 2 price monitoring
It's been a tedious wait for the last couple of years but hopefully we are about to realise some value. GLA
NSCI is one of the most undervalued shares on the market asset backed with NAV at £2+ and massive upside that too.
Investors can't add up and don't have the patience or foresight sadly. Happy to wait for huge gains
well thats that can gone oh and a £19k buy now there's confidence
lonely im so lonely lol
£2 a while ago might get something big and get back to where we were.
I am talking to myself but another can of special brew and I’ll have my imaginary friend back lol
Only 23mil shares could get interesting
This has got to be cheap things are warming up
Simon T has just announced (after market closed) his 8 shares to make the 2023 bargain shares portfolio which includes NSCI. Expect more upward movement tomorrow on the back of the article.
https://www.investorschronicle.co.uk/ideas/2023/02/09/bargain-shares-2023/
GLA
https://www.investorschronicle.co.uk/ideas/2023/02/09/bargain-shares-2023/
NSCI makes the list!
what news?
News
This has got so much goin on
Great but need figures/forecasts - means nothing when assessing value.
I thought the presentation was poor and unambitious - peeps want big deals not 100k here and there - and they have one Glyco - which was not mentioned, forecast market penetration ignore - delays not explained [3 years] - why ?
A better share price means they can raise with min dilution and be more agressive.
This is a PDS margin play atm and will be until they get some balls.
Sofant? Its brilliant but silience - even a kid could sell the co better.